NEW UK PRIME MINISTER NOT THE LEADER BRITAIN NEEDS — KEMI BADENOCH. (PHOTO)

Image
 New UK Prime Minister not the leader Britain needs — Kemi Badenoch UK Conservative Party leader, Kemi Badenoch, has congratulated Andy Burnham on becoming Britain’s new prime minister but said while he is “a nice man,” the country needs a leader capable of making difficult decisions rather than “a people pleaser.” In a statement released on Monday on X following Burnham’s assumption of office, Badenoch wished the new prime minister success but vowed to hold his government accountable as Leader of the Opposition. “Today, Britain has a new Prime Minister. I wish Andy Burnham every success. Because we need a Prime Minister and a Government focused on fixing the public’s priorities,” she said. Badenoch said her role was “to hold the Prime Minister to account, not to be his cheer leader.” “My job as Leader of the Opposition, is to hold the Prime Minister to account, not to be his cheer leader. When he does the right thing, I will praise him,” she stated. She welcomed reports that Burnh...

EU REGULATOR APPROVES INJECTABLE HIV DRUG AIMED AT PREVENTING TRANSMISSION. (PHOTO).


 EU regulator approves injectable HIV drug aimed at preventing transmission

The European Medicines Agency has recommended the approval of a twice-yearly injectable drug designed to prevent HIV infection, a development that researchers believe could significantly curb transmission of the virus. The drug, lenacapavir, which will be marketed in Europe under the name Yeytuo by Gilead Sciences, was described by the agency as “highly effective” and of “major public health interest.” If the European Commission accepts this guidance, the authorization will apply across all 27 EU countries, as well as Iceland, Norway, and Liechtenstein. Clinical studies conducted last year showed that lenacapavir, already used to treat individuals living with HIV, was almost 100% effective in preventing transmission in both men and women.


Public health officials, including Winnie Byanyima, the executive director of the United Nations AIDS agency, have described lenacapavir as a potential game changer in the fight against HIV, provided that it is made widely accessible. The drug, which was authorized for prevention by the U.S. Food and Drug Administration in June, has also been recommended by the World Health Organization as an additional option for people at risk. Unlike daily preventive pills or cabotegravir injections that must be administered every two months, lenacapavir provides protection for six months with a single injection, a feature that could appeal to those who prefer fewer clinic visits and less stigma. Despite its promise, critics have expressed concerns that Gilead’s plan to allow generic production in 120 low-income countries does not cover much of Latin America, where HIV rates, though lower, are rising. UNAIDS estimates that more than 40 million people worldwide live with HIV, with about 630,000 deaths from AIDS-related illnesses reported last year, and has urged global leaders, including President Donald Trump, to work toward making this long-lasting prevention option accessible to those who need it most.


Comments

Popular posts from this blog

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.